Atherosclerotic Cardiovascular Disease Clinical Trials in Beijing
5 recruitingBeijing, China
Showing 1–5 of 5 trials
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Atherosclerotic Cardiovascular Disease
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled751 locationsNCT07157774
Recruiting
Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients
Cardiovascular DiseasesAtherosclerotic Cardiovascular Disease (ASCVD)Secondary Prevention
Peking University First Hospital5,448 enrolled1 locationNCT07542860
Recruiting
Phase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled92 locationsNCT06813911
Recruiting
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
Major Cardiovascular EventEstablished Atherosclerotic Cardiovascular Disease
Amgen7,000 enrolled90 locationsNCT06295679